LLY
Lilly brought the whole oncology suitcase
Eli Lilly is heading into the 2026 ASCO Annual Meeting with more than a booth and a name tag. The company says it will showcase data across lung, breast, and blood cancers, with two presentations landing in the Plenary Session — the conference’s equivalent of the front-row table at the industry’s fanciest dinner.
The headline item is the Phase 3 LIBRETTO-432 study for Retevmo (selpercatinib) in RET fusion-positive non-small cell lung cancer. Lilly says the study’s primary event-free survival results will get a Plenary Session spotlight, which is the kind of stage that can turn a drug from “pipeline promise” into “okay, this might matter.”
Verzenio gets a turn in the spotlight
Lilly is also bringing an investigator-initiated Phase 3 study, SARC041, looking at Verzenio (abemaciclib) in patients with advanced dedifferentiated liposarcoma. That’s a rare cancer setting, sure, but investors know the game: every new indication is another shot at squeezing more life out of a big-name asset.
And because Lilly apparently didn’t think one ASCO splash was enough, the company says Kelonia Therapeutics — which Lilly has agreed to acquire — will present updated data for its BCMA-targeted in vivo CAR-T therapy in relapsed and refractory multiple myeloma. That’s a reminder that Lilly’s oncology ambitions are no longer just about pills and antibodies; it wants a seat at the cell-therapy table too.
Why investors should care
Conference season can be a vibes market, but the vibes matter. Positive readouts and prominent presentation slots can support the bull case for Lilly’s cancer pipeline, while weaker-than-hoped data can dull the shine on future growth stories.
The bigger picture: Lilly is trying to look less like a one-drug superstar and more like a full-stack pharma platform. If ASCO goes well, it’s another reminder that the company’s growth story isn’t only about obesity — oncology is very much part of the sequel.